Results 61 to 70 of about 3,663 (172)

The Concise Guide to PHARMACOLOGY 2025/26: Enzymes

British Journal of Pharmacology, Volume 182, Issue S1, Page S307-S403, December 2025.
The Concise Guide to Pharmacology 2025/26 marks the seventh edition in this series of biennial publications in the British Journal of Pharmacology. Presented in landscape format, the guide provides a comparative overview of the pharmacology of drug target families. The concise nature of the Concise Guide refers to the style of presentation, being clear,
Stephen P. H. Alexander, Doriano Fabbro, Alasdair J. Gibb, Eamonn Kelly, Alistair A. Mathie, Chloe J. Peach, Emma L. Veale, Jane F. Armstrong, Elena Faccenda, Simon D. Harding, Christopher Southan, Jamie A. Davies, Stephanie Annett, Detlev Boison, Kathryn Elisa Burns, Carmen Dessauer, Jürg Gertsch, Nuala Ann Helsby, Angelo A. Izzo, Rennolds Ostrom, Ester Pagano, Andreas Papapetropoulos, Nigel J. Pyne, Susan Pyne, Tracy Robson, Roland Seifert, Johannes‐Peter Stasch, Csaba Szabo, Mario van der Stelt, Albert van der Vliet, Val Watts, Szu Shen Wong   +31 more
wiley   +1 more source

Life Factors and Melanoma: From the Macroscopic State to the Molecular Mechanism

Advanced Science, Volume 12, Issue 43, November 20, 2025.
Melanoma, an aggressive skin cancer, arises from dynamic interactions between genetic, environmental, and lifestyle factors. This review explores how age, gender, obesity, diet, exercise, smoking, alcohol, UV exposure, circadian rhythms, and medications influence melanoma risk and progression.
Hanbin Wang, Hengxiang Zhang, Yuqi Zhou, Chunying Li, Weinan Guo   +4 more
wiley   +1 more source

Systematic Review and Network Meta‐Analysis on the Efficacy of Evolocumab and Other Therapies for the Management of Lipid Levels in Hyperlipidemia

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2017
BackgroundThe proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors evolocumab and alirocumab substantially reduce low‐density lipoprotein cholesterol (LDL‐C) when added to statin therapy in patients who need additional LDL‐C reduction ...
Peter P. Toth, Gillian Worthy, Shravanthi R. Gandra, Naveed Sattar, Sarah Bray, Lung‐I. Cheng, Ian Bridges, Gavin M. Worth, Ricardo Dent, Carol A. Forbes, Sohan Deshpande, Janine Ross, Jos Kleijnen, Erik S. G. Stroes   +13 more
doaj   +1 more source

Effects of Alirocumab and Evolocumab on Cardiovascular Mortality and LDL-C: Stratified According to the Baseline LDL-C Levels

Reviews in Cardiovascular Medicine
Background: A meta-analysis was conducted to determine whether the cardiovascular mortality and lipid-lowering effects of alirocumab and evolocumab are influenced by various baseline low-density lipoprotein cholesterol (LDL-C) levels.
Hui Ma, Wenfang Ma, Yang Liu, Lixing Chen, Peng Ding   +4 more
doaj   +1 more source

Alirocumab in Polyvascular Atherosclerotic Disease

Journal of the American College of Cardiology, 2020
Jukema et al. ([1][1]) demonstrated in a pre-specified analysis from the ODYSSEY-OUTCOMES (Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab) trial that alirocumab was associated with absolute risk reduction (ARR) in cardiovascular ...
openaire   +2 more sources

Alirocumab Treatment and Achievement of Non‐High‐Density Lipoprotein Cholesterol and Apolipoprotein B Goals in Patients With Hypercholesterolemia: Pooled Results From 10 Phase 3 ODYSSEY Trials

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2017
BackgroundNon‐high‐density lipoprotein cholesterol (non‐HDL‐C) and apolipoprotein (apo) B are better predictors of atherosclerotic cardiovascular disease risk than low‐density lipoprotein cholesterol alone.
Harold E. Bays, Lawrence A. Leiter, Helen M. Colhoun, Desmond Thompson, Laurence Bessac, Robert Pordy, Peter P. Toth   +6 more
doaj   +1 more source

Time to achieve target lipid metabolism parameters and its impact on long-term outcomes after acute coronary syndrome in conditions of multicomponent lipid-lowering therapy

Терапевтический архив
Aim. To evaluate the effect of the initiation time of lipid-lowering therapy (LLT) with the use of the proprotein convertase subtilisin/kexin type 9 (iPCSK9) inhibitor alirocumab on the incidence of adverse outcomes during 18-month follow-up after acute ...
Aleksei A. Nekrasov, Elena S. Timoshchenko, Svetlana G. Erofeeva, Tatiana A. Nekrasova, Fazliniso N. Muradova, Elena S. Kuzyakina   +5 more
doaj   +1 more source

The roles of apo(a) size, phenotype, and dominance pattern in PCSK9-inhibition-induced reduction in Lp(a) with alirocumab[S]

Journal of Lipid Research, 2017
An elevated level of lipoprotein (a) [Lp(a)] is a risk factor for CVD. Alirocumab, a monoclonal antibody to proprotein convertase subtilisin/kexin type 9, is reported to reduce Lp(a) levels.
Byambaa Enkhmaa, Erdembileg Anuurad, Wei Zhang, Kun Yue, Ching-Shang Li, Lars Berglund   +5 more
doaj   +1 more source

Efficacy and Safety of Evolocumab and Alirocumab as PCSK9 Inhibitors in Pediatric Patients with Familial Hypercholesterolemia: A Systematic Review and Meta-Analysis

Medicina
Background and Objectives: The proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors evolocumab and alirocumab are recently developed promising drugs used for treatment of familial hypercholesterolemia (FH).
Guoguang Xiao, Shan Gao, Yongmei Xie, Zhiling Wang, Min Shu   +4 more
doaj   +1 more source

Protective effect of alirocumab, a PCSK9 inhibitor, on the sciatic nerve of rats with diabetic peripheral neuropathy

Endocrine Journal
Dyslipidemia has been considered a risk factor for diabetic peripheral neuropathy. Proprotein convertase subtilisin-like/Kexin 9 inhibitor (PCSK9) inhibitors are a new type of lipid-lowering drug currently in clinical use.
Na Cui, Yonghao Feng, Ming Wang, Xiuyan Lu, Yongmei Huang, Yinghui Chen, Xiaohong Shi   +6 more
doaj   +1 more source